Author:
Matyskin Artem V.,Angermeier Susanna B.,Drera Saleem S.,Prible Michael C.,Geuther Jeffrey A.,Heibel Michael D.
Funder
Westinghouse Electric Company
Reference52 articles.
1. The promise of targeted α-particle therapy;Mulford;J Nucl Med,2005
2. Actinium-225 for targeted α therapy: coordination chemistry and current chelation approaches;Thiele;Cancer Biother Radiopharm,2018
3. Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted alpha-radiation therapy;van der Doelen;Urol Oncol Semin Orig Investig,2021
4. FDA approval summary: lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer;Fallah;Clin Cancer Res,2023
5. 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer;Kratochwil;J Nucl Med,2016